CONFIDENTIAL INVESTOR DOCUMENT — 2025
AUREOM
The first platform for autonomic nervous system regulation. Real-time adaptive physiological coherence technology — for the largest unsolved market of our era: silent chronic nervous dysregulation.
01
THE PROBLEM
The great health problem of our era is not disease.
It is silent chronic nervous dysregulation.
Millions of people live functional on the outside and physiologically exhausted on the inside. They sleep but don't recover. They rest but don't repair. The nervous system never leaves the state of chronic vigilance.
80%+
Western adults with chronically reduced HRV
322M
people with diagnosed anxiety globally
1/3
adults with chronic sleep disorders
$615B
annual cost of global corporate burnout
— First, the depth of rest disappears.
— Then mental clarity and emotional stability.
— Then comes sustained fatigue, inflammation, exhaustion.
— The body works. But it needs more and more effort to produce less and less wellbeing.
The body has not forgotten how to be in coherence.
It has just spent too long surviving.
02
THE MARKET
AUREOM does not compete in wellness. It creates a new category.
The target market is not sick people. They are functional but physiologically exhausted people — the largest, most solvent and most underserved audience in the world.
| SEGMENT | PROFILE | MAIN PAIN | WILLINGNESS |
|---|---|---|---|
| Founders & executives | Chronic high cognitive load | Burnout, lack of clarity, insomnia | High |
| High performance athletes | Neural and autonomic recovery | Over-training, systemic fatigue | Very high |
| Creatives & artists | Creative hyperactivation | Block, anxiety, fragmentation | Medium-high |
| Healthcare professionals | Vicarious trauma, compassion fatigue | Clinical burnout, dysregulation | High |
| Longevity market | Biological optimization | Aging, vitality | Very high |
$650B
Global digital wellness market 2025 (+10% annual)
$610B
Premium longevity industry by 2030
$70B/year
Corporate wellness USA + Europe
AUREOM does not pursue that market. It redefines it. Not as wellness. As physiological infrastructure for human performance.
03
THE SOLUTION
AUREOM is the first adaptive physiological coherence platform that works on the three body systems simultaneously, in the biologically correct order, adjusting in real time to each user's physiological response.
LISTEN FIRST
The system measures HRV, EEG and breathing before activating any stimulus. It only acts when the body confirms it is ready to receive.
CLOSED LOOP
Each stimulus is adjusted in real time according to the actual brain and cardiac response. There is no fixed protocol. There is continuous dialogue with the user's biology.
THREE STATES IN ORDER
Autonomic descent → Neural entrainment → Theta consolidation. The order physiology demands. What no current system respects.
Measured results in session:
15-35%
HRV increase with 6-12h effect
7-10 min
to gamma coherence vs 10-15 min standard
4-6
sessions for documented stable change
89%+
users report sleep improvement
04
WHY NO ONE ELSE DOES THIS
The market is full of partial technologies. None closes the complete loop.
| Meditation Apps | Neurofeedback | PEMF/Light | HRV Biofeedback | AUREOM | |
|---|---|---|---|---|---|
| Real-time measurement | — | Partial | — | Yes | Yes |
| Adaptive adjustment | — | — | — | — | Yes |
| Works 3 systems | — | — | — | — | Yes |
| Biological order | — | — | — | — | Yes |
| Consolidates state | — | Partial | — | — | Yes |
| Digitally scalable | Yes | — | — | Partial | Yes |
| Longitudinal data | — | — | — | — | Yes |
The barrier to entry is not the hardware. It is the protocol. The closed-loop architecture over three simultaneous systems, with correct biological order, is AUREOM's real intellectual property. That cannot be copied by buying components.
05
BUSINESS MODEL
AUREOM is a recurring revenue ecosystem with five layers. The physical center validates and generates brand. The digital layer scales globally.
01 — Flagship
Product
25 min in-person session
Price
€80-150
Margin
60-70%
Scale
Local / regional
02 — Membership
Product
Monthly pack 4-8 sessions
Price
€250-600/month
Margin
65-75%
Scale
Local / regional
03 — Corporate
Product
AUREOM room in company + measured protocol
Price
€3,000-8,000/month
Margin
70-80%
Scale
Scalable B2B
04 — AUREOM Home (SaaS + hardware)
Product
Daily regulation app + basic device
Price
€20-50/month + €400-800 hardware
Margin
80-90%
Scale
Unlimited global
05 — Clinical licenses
Product
Protocol + software for clinics
Price
€500-2,000/month
Margin
85-90%
Scale
Global B2B
The growth engine is the flywheel: the flagship generates transformation and content → content attracts digital users → data improves the protocol → the protocol strengthens the flagship. Each layer feeds the others.
06
CAPITAL ARCHITECTURE
AUREOM does not need capital to build. It needs minimal capital to demonstrate. The entry risk is extraordinarily low.
MVP VALIDATION
€80,000
Functional prototype. Partnership with existing space. First 50-100 users. Real physiological evidence: HRV, EEG, coherence, recurrence. Content from day one.
PRO PROTOTYPE + DIGITAL LAYER
€150,000 - €250,000
Refined hardware. First semi-owned space. Active memberships. AUREOM Home app in beta. First corporate contracts. Longitudinal data from 200+ users.
FLAGSHIP + SCALE
€300,000 - €500,000
Iconic space. Consolidated brand. Active SaaS with first 5,000 digital subscribers. Clinical licenses. Expansion to second city. International pipeline.
GLOBAL SCALE
To be defined with traction
Dominant SaaS. Home hardware. License expansion. Data & analytics. Category positioning. The iOS of the nervous system.
Most importantly: with €80,000 we can demonstrate that the body responds, that metrics change and that people want to come back. If that happens, the rest is expansion. There is no other real risk.
07
FINANCIAL PROJECTION
Conservative scenario. Organic growth. Scale engine: the digital layer starting year 3.
| YEAR | USERS | REVENUE | EXPENSES | RESULT | KEY MILESTONE |
|---|---|---|---|---|---|
| 1 | 300-600 | €45K-90K | €80K-140K | -€40K/-60K | Evidence and brand |
| 2 | 1,500-3,000 | €250K-500K | €220K-420K | +€30K/+80K | First break-even |
| 3 | 6,000-12,000 | €1.2M-2.5M | €700K-1.5M | +€500K/+1M | Active SaaS |
| 4 | 20,000-50,000 | €4M-8M | €2M-4.5M | +€2M/+3.5M | Digital scale |
| 5 | 80,000-200,000 | €12M-30M | €5M-14M | +€7M/+16M | Complete ecosystem |
The inflection point is year 3, when the digital layer begins to dominate. With just 50,000 digital users at €20/month = €12M/year recurring, not counting centers, hardware or licenses.
08
THE VISION
Right now AUREOM looks like advanced wellness technology. The real potential is something else.
A new cultural language
If we get people to say "I need to regulate" instead of "I need to rest", we have won culturally. Great companies create words. AUREOM can create a category.
A human data platform
With enough volume, AUREOM can detect burnout before symptoms, cognitive fatigue, depressive states, recovery capacity. That is not wellness. It is applied physiological intelligence.
The new status symbol
The luxury of the future is not time or money. It is a coherent nervous system. AUREOM can become the equivalent of the private trainer for the nervous system for the new elite of human performance.
The iOS of the nervous system
Hardware + software + adaptive AI + nervous profiles + personalized sessions + physiological history + state prediction. Not just a device. A human regulation operating system.
We are not building wellness technology.
We are building a new relationship between human beings and their own nervous system.
That is the biggest thing.
Full coherence is not a state that AUREOM produces.
It is a state that the body produces when given the right conditions, in the right order, with the right listening.
AUREOM creates those conditions. The body, guided by its own original design, does the rest.
NEXT STEP
We invite a direct conversation to share the detailed technical prototype, the validation protocol and the terms of participation in the MVP phase.
AUREOM — Confidential investor document. The information contained in this document is confidential and intended exclusively for designated recipients.